<DOC>
	<DOCNO>NCT01370603</DOCNO>
	<brief_summary>The purpose study determine whether ezetimibe/atorvastatin 10 mg/40 mg combination tablet equivalent coadministration ezetimibe 10 mg atorvastatin 40 mg lower low-density-lipoprotein-cholesterol ( LDL-C ) 6 week treatment .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared Marketed Ezetimibe 10 mg Atorvastatin 40 mg Tablets Participants With High Cholesterol ( MK-0653C-190 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Inclusion criterion : At low , moderate , moderately high cardiovascular risk ( accord National Cholesterol Education Program adult treatment panel III [ NCEP ATP III ] guideline ) either statinnaïve LDLC ≥130 mg/dL low risk ≥100 mg/dL moderate moderately high risk OR allowable statin ontherapy LDLC ≥100 mg/dL acceptable range safely discontinue switch study medication . Is willing maintain cholesterollowering diet throughout study . Female reproductive potential agrees remain abstinent use ( partner use ) 2 acceptable method birth control throughout study . Female receive noncyclical hormone therapy , maintain stable dose regimen least 8 week prior study willing continue regimen throughout study . Offtherapy LDLC level : low risk patient , ≥130 mg/dL ≤300 mg/dL ; moderate risk patient , ≥100 mg/dL ≤300 mg/dL ; moderately high risk patient , ≥100 mg/dL ≤275 mg/dL . Has liver transaminases ≤2 X upper limit normal ( ULN ) active liver disease . Has creatine kinase ( CK ) level ≤3 X ULN . Has triglyceride ( TG ) concentration ≤400 mg/dL . Exclusion criterion : Hypersensitivity intolerance ezetimibe , atorvastatin , ezetimibe/atorvastatin combination tablet , component medication , history myopathy rhabdomyolysis ezetimibe statin . Routinely consume 2 alcoholic drink per day ( average &gt; 14 alcoholic drink per week ) . Is pregnant lactating . Has treat investigational drug within 30 day study . Is high risk ( accord NCEP ATP III guideline ) , include limited one following : diabetes mellitus ( Type I II ) , myocardial infarction , coronary artery bypass surgery , angioplasty , stable unstable angina . Has follow medical condition : congestive heart failure ; uncontrolled cardiac arrhythmia recent significant change electrocardiogram ( ECG ) ; homozygous familial hypercholesterolemia undergone LDL apheresis ; partial ileal bypass , gastric bypass , significant intestinal malabsorption ; uncontrolled hypertension ; kidney disease ; disease know influence serum lipid lipoproteins ; hematologic , digestive , central nervous system disorder ; know human immunodeficiency virus ( HIV ) positive ; history malignancy ≤5 year prior study , except adequately treat basal cell squamous cell skin cancer situ cervical cancer ; mental instability , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . Taking prohibited medications/foods include : systemic azole antifungal ( e.g. , fluconazole , ketoconazole ) , erythromycin clarithromycin , cyclosporine ; ritonavir saquinavir lopinavir ; &gt; 5 cup grapefruit juice per day ; combination therapy ezetimibe + atorvastatin ( 10/80 mg ) ezetimibe + rosuvastatin ( 10/20 mg 10/40 mg ) ; nonstatin lipidlowering agent include fish oil contain &gt; 900 mg/day eicosapentaenoic acid docosahexaenoic acid ( EPA+DHA ) , red yeast extract , Cholestin™ , bile acid sequestrants , cholesterollowering agent , niacin ( &gt; 200 mg/day ) , fibrates ; systemic corticosteroid ; psyllium , fiberbased laxative , phytosterol margarine , and/or counter ( OTC ) therapies know affect serum lipid level ; orlistat antiobesity medication maintain stable dose ; cyclical hormone ; warfarin treatment without stable dose stable International Normalized Ratio ( INR ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>